HRH1
Histamine H1 receptor
As of the edition of 20 October 2026, HRH1 (histamine H1 receptor, UniProt P35367) has 65 drugs tested at it and 67 companies on the list, 1 on route A and 19 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P35367
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 9
- Disease areas
- Immune system; Lungs and airways; Ear, nose and throat; Skin and connective tissue; Cancer; Infections; Nervous system; Eye
- Registered trials of its drugs
- 829
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 56 |
| Went quiet | 3 |
| Stopped | 1 |
| Withdrawn from market | 5 |
| Total | 65 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Diphenhydramine | Marketed | Phase 4 | none listed |
| Cetirizine | Marketed | Phase 4 | none listed |
| Fexofenadine | Marketed | Phase 4 | none listed |
| Desloratadine | Marketed | Phase 4 | none listed |
| Levocetirizine | Marketed | Phase 4 | none listed |
| Loratadine | Marketed | Phase 4 | none listed |
| Azelastine | Marketed | Phase 4 | none listed |
| Histamine | Marketed | Phase 4 | none listed |
| Olopatadine | Marketed | Phase 4 | none listed |
| Terfenadine | Withdrawn from market | Phase 4 | none listed |
| Promethazine | Marketed | Phase 4 | none listed |
| Ketotifen | Marketed | Phase 4 | none listed |
12 of 65 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 19 |
| Engaged | 11 |
| Undetermined | 36 |
| Total on the list | 67 |
| Company | Route |
|---|---|
| Merck & Co. | Route B |
| Pfizer | Route B |
| Hisamitsu Pharmaceutical | Route B |
The other 64 companies at HRH1
In the product67 companies in all; 64 are not named here, and no score is.
See the 67 companies at HRH1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.